FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background/aims: In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. Methods: We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM method. Resulting single-subject SPM maps were classified by five imaging experts according to the disease-specific patterns, as "typical-AD", "atypical-AD" (i.e. posterior cortical atrophy, asymmetric logopenic AD variant, frontal-AD variant), "non-AD" (i.e. behavioural variant FTD, corticobasal degeneration, semantic variant FTD; dementia with Lewy bodies) or "negative" patterns. To perform the statistical analyses, the individual patterns were grouped either as "AD dementia vs. non-AD dementia (all diseases)" or as "FTD vs. non-FTD (all diseases)". Aβ42, total and phosphorylated Tau CSF-levels were classified dichotomously, and using the Erlangen Score algorithm. Multivariate logistic models tested the prognostic accuracy of FDG-PET-SPM and CSF dichotomous classifications. Accuracy of Erlangen score and Erlangen Score aided by FDG-PET SPM classification was evaluated. Results: The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I. 4.8-77.8, p < 0.001) and CSF Aβ42 (Expβ = 6.5, 95% C.I. 1.64-25.43, p < 0.05) as the best predictors of conversion from MCI to AD dementia. The "FTD" SPM pattern significantly predicted conversion to FTD dementias at follow-up (Expβ = 14, 95% C.I. 3.1-63, p < 0.001). Overall, FDG-PET-SPM classification was the most accurate biomarker, able to correctly differentiate either the MCI subjects who converted to AD or FTD dementias, and those who remained stable or reverted to normal cognition (Expβ = 17.9, 95% C.I. 4.55-70.46, p < 0.001). Conclusions: Our results support the relevant role of FDG-PET-SPM classification in predicting progression to different dementia conditions in prodromal MCI phase, and in the exclusion of progression, outperforming CSF biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 6×
“To overcome this limit, diagnostic biomarkers such as neuroimaging (i.e., MRI, FDG-PET and amyloid-PET) and cerebrospinal fluid-CSF (i.e., Aβ42, total (t-Tau) and phosphorylated (p-Tau) Tau measures) have been included in the current research criteria for “MCI due to AD” (Albert et al., 2011).”
BackgroundInfluentialA New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056 · cited 1×
“…at baseline, made in accordance with Petersen criteria (Petersen et al., 2009); (2) Washington University Clinical Dementia Rating (CDR) scale= 0.5 (Hughes et al., 1982); (3) detailed clinical, neuropsychological and neurobehavioral assessment at baseline; (3) FDG-PET imaging performed within 6…”
MethodInfluentialSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · cited 4×
“…at follow-up was obtained according to the current diagnostic criteria for each dementia type (Armstrong et al., 2013; Gorno-Tempini et al., 2011; Litvan et al., 1996; McKeith et al., 2017; McKhann et al., 2011a; Rascovsky et al., 2011), and constituted the reference standard for the present study.”
BackgroundMethodInfluentialClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“…patterns that are accurately detected by FDGPET (Caminiti et al., 2017; Cerami et al., 2016, 2017; Iaccarino et al., 2015; Perani, 2014; Perani et al., 2016; Teipel et al., 2015; Teune et al., 2010), even before manifest brain atrophy (Bateman et al., 2012; Chételat et al., 2008; Perani, 2014).”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 3×
“Since AD dementia constitutes only one of the possible clinical outcomes for MCI condition (Mitchell and Shiri-Feshki, 2009), data on validated biomarker accuracy for risk progression to different dementias in a large prodromal MCI sample are necessary, and currently lacking.”
BackgroundInfluentialPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 2×
“FDG-PET is a highly specific biomarker of neurodegeneration, thus able to detect typical and atypical AD dementia, as well as many non-AD dementia conditions, even in the preclinical and prodromal phase (Arbizu et al., 2013; Bohnen et al., 2012; Caroli et al., 2012; Cerami et al., 2015; Hinrichs et al., 2011; Mosconi…”
BackgroundComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · cited 9×
“…FDG-PET in MCI conversion to AD dementia varied widely and ranged from 25% to 100% for sensitivity and from 15% to 100% for specificity (Anchisi et al., 2005; Arbizu et al., 2013; Chen et al., 2016; Chételat et al., 2003; Landau et al., 2010; Ossenkoppele et al., 2013; Perani et al., 2014a, 2016).”
BackgroundResultInfluentialConversion from subtypes of mild cognitive impairment to Alzheimer dementia
Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., & Tragl, K. H. (2007) · Neurology · doi:10.1212/01.wnl.0000252358.03285.9d · Cited by 471
Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374 · cited 1×
“In the future, optimized automated methods for CSF quantification might reduce inter-centres analytical variability (Bittner et al., 2016).”
MethodVanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358 · cited 2×
“, diagnostic procedures, samples processing and testing) challenge the validity and comparability of CSF results among different laboratories (Vanderstichele et al., 2012).”
BackgroundSelf-citationReview and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110458 · Cited by 282
Young, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249 · cited 1×
“…combining FDG-PET and CSF markers, are limited and strictly focused on conversion to AD dementia (Chen et al., 2016; Choo et al., 2013; Galluzzi et al., 2013; Gomar et al., 2014; Landau et al., 2010; Prestia et al., 2013a; Shaffer et al., 2013; Walhovd et al., 2010; Young et al., 2013).”
BackgroundBrain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236 · cited 2×
“altered intracellular signalling cascades, mitochondria bioenergetics, impaired neurotransmitter release, and proteinopathies (Kato et al., 2016; Perani, 2014).”
BackgroundImpact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.003 · Cited by 194 · cited 1×
“…FDG-PET in MCI conversion to AD dementia varied widely and ranged from 25% to 100% for sensitivity and from 15% to 100% for specificity (Anchisi et al., 2005; Arbizu et al., 2013; Chen et al., 2016; Chételat et al., 2003; Landau et al., 2010; Ossenkoppele et al., 2013; Perani et al., 2014a, 2016).”
BackgroundPrediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184
Self-citationRecommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138
Self-citationA Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives
On behalf of the European Association of Nuclear Medicine, Morbelli, S., Garibotto, V., Van De Giessen, E., Arbizu, J., Chételat, G., Drezgza, A., Hesse, S., Lammertsma, A. A., Law, I., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3098-2 · Cited by 61 · cited 4×
“…Medicine (EANM) stated that even if a clear variability in diagnostic performance of FDG-PET is reported in the literature, it is not attributable to the method itself, but rather to a number of factors such as study design, definitions of MCI and data analysis procedures (Morbelli et al., 2015).”
BackgroundInfluentialIaccarino, L., Crespi, C., Della Rosa, P. A., Catricalà, E., Guidi, L., Marcone, A., Tagliavini, F., Magnani, G., Cappa, S. F., & Perani, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120197 · Cited by 56 · cited 1×
“…alterations with consistent disease-specific patterns that are accurately detected by FDGPET (Caminiti et al., 2017; Cerami et al., 2016, 2017; Iaccarino et al., 2015; Perani, 2014; Perani et al., 2016; Teipel et al., 2015; Teune et al., 2010), even before manifest brain atrophy (Bateman et…”
BackgroundSelf-citationTang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38
Cited by
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Self-citationvan Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
“Additionally, this heterogeneity turned out to be of value in predicting progression to different forms of dementia in the prodromal MCI phase [170].”
BackgroundDisentangling Heterogeneity in Alzheimer’s Disease and Related Dementias Using Data-Driven Methods
Habes, M., Grothe, M. J., Tunc, B., McMillan, C., Wolk, D. A., & Davatzikos, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.016 · Cited by 167
Neuroimaging and Machine Learning for Dementia Diagnosis: Recent Advancements and Future Prospects
Ahmed, M. R., Zhang, Y., Feng, Z., Lo, B., Inan, O. T., & Liao, H. (2019) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2018.2886237 · Cited by 142
Metadata
- Authors
- Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., Magnani, G., Perani, D., Parnetti, L., Eusebi, P., Frisoni, G., Nobili, F., Picco, A., & Scarpini, E.
- Venue
- NeuroImage: Clinical
- Publisher
- Elsevier BV
- Published
- 2018
- Volume
- 18
- Pages
- 167-177
- ISSN
- 2213-1582 (ISSN-L)
- OpenAlex
- W2790567468
- Cited by
- 147
- References
- 27
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.